🇺🇸 FDA
Patent

US 12011437

Roflumilast formulations with an improved pharmacokinetic profile

granted A61KA61K31/44A61K45/06

Quick answer

US patent 12011437 (Roflumilast formulations with an improved pharmacokinetic profile) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARCUTIS BIOTHERAPEUTICS, INC.
Grant date
Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/44, A61K45/06, A61K47/10, A61K47/24